Infliximab does not suppress the tuberculin skin test (purified protein derivative)

Journal of Rheumatology

Volumn 34, Issue 3, 2007, Pages 474-480

  Hatemi, Gulen ^a   Melikoglu, Melike ^a   Fresko, Izzet ^a   Masatlioglu, Seval ^c   Tascilar, Koray ^a   Yazici, Hasan ^b,d  

^a Department of Rheumatology ^*

^b ISTANBUL UNIVERSITY   (Turkey)

^c HAYDARPASA NUMUNE HOSPITAL   (Turkey)

^d ISTANBUL UNIVERSITY   (Turkey)

Author keywords

Beh et's disease; Infliximab; Purified protein derivative; Rheumatoid arthritis; Tuberculin skin test; Tuberculosis; Tumor necrosis factor alpha inhibitor

Indexed keywords

AZATHIOPRINE; CYCLOSPORIN; HYDROXYCHLOROQUINE; INFLIXIMAB; LEFLUNOMIDE; METHOTREXATE; PREDNISOLONE; SALAZOSULFAPYRIDINE; TUBERCULIN; TUMOR NECROSIS FACTOR ALPHA INHIBITOR;

ADULT; ANKYLOSING SPONDYLITIS; ANTIINFLAMMATORY ACTIVITY; AORTA ARCH SYNDROME; ARTICLE; BEHCET DISEASE; CROHN DISEASE; FEMALE; HUMAN; IMMUNOTHERAPY; IN VITRO STUDY; MAJOR CLINICAL STUDY; MALE; OBSERVER VARIATION; PRIORITY JOURNAL; PSORIATIC ARTHRITIS; RHEUMATOID ARTHRITIS; SKIN INDURATION; SKIN MANIFESTATION; TREATMENT OUTCOME; TUBERCULIN TEST;

ADULT; ANTI-INFLAMMATORY AGENTS; ANTIBODIES, MONOCLONAL; ARTHRITIS, RHEUMATOID; FEMALE; HUMANS; HYPERSENSITIVITY, DELAYED; MALE; MIDDLE AGED; MYCOBACTERIUM BOVIS; OBSERVER VARIATION; REPRODUCIBILITY OF RESULTS; TUBERCULIN TEST;

EID: 33847646292     PISSN: 0315162X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (22)

1. Keane J, Gershon S, Wise RP, et al. Tuberculosis associated with infliximab, a tumor necrosis factor alpha-neutralizing agent. N Engl J Med 2001;345:1098-104.
2. Gomez-Reino JJ, Carmona L, Valverde VR, Mola EM, Montero MD, BIOBADASER Group. Treatment of rheumatoid arthritis with tumor necrosis factor inhibitors may predispose to significant increase in tuberculosis risk: a multicenter active-surveillance report. Arthritis Rheum 2003;48:2122-7.
3. Long R, Gardam M. Tumour necrosis factor-alpha inhibitors and the reactivation of latent tuberculosis infection. CMAJ 2003;168:1153-6.
4. Furst DE, Cush J, Kaufmann S, Siegel J, Kurth R. Preliminary guidelines for diagnosing and treating tuberculosis in patients with rheumatoid arthritis in immunosuppressive trials or being treated with biological agents. Ann Rheum Dis 2002;61 Suppl 2:ii62-3.
5. Mariette X, Salmon D. French guidelines for diagnosis and treating latent and active tuberculosis in patients with rheumatoid arthritis treated with TNF blockers. Ann Rheum Dis 2003;62:791.
6. Orme IM, Cooper AM. Cytokine/chemokine cascades in immunity to tuberculosis. Immunol Today 1999;20:307-12.
7. Long R, Gardam M. Tumor necrosis factor-alpha inhibitors and the reactivation of latent tuberculosis infection. CMAJ 2003;168:1153-6.
8. Keser G, Direskeneli H, Akkoc N, et al. TNF-a Engelleyici Ilaç Kullanan Olgularin Tedavi Öncesinde Tüberküloz Açisindan Degerlendirilmesi ve Alinmasi Gerekli Önlemler. RAED II. Uzlasi Toplantisi Raporu. 2005 May.
9. Slutkin G, Perez-Stable EJ, Hopewell PC. Time course and boosting of tuberculin reactions in nursing home residents. Am Rev Respir Dis 1986;134:1048-51.
10. American Thoracic Society, Centers for Disease Control. Targeted tuberculin testing and treatment of latent tuberculosis infection. Am J Respir Crit Care Med 2000;161:S221-47.
11. Thompson NJ, Glassroth JL, Snider DE Jr, Farer LS. The booster phenomenon in serial tuberculin testing. Am Rev Respir Dis 1979;119:587-97.
12. Wauters A, Peetermans WE, Van den Brande P, et al. The value of tuberculin skin testing in haemodialysis patients. Nephrol Dial Transplant 2004;19:433-8.
13. Hoft DF, Tennant JM. Persistence and boosting of bacille Calmette-Guerin-induced delayed-type hypersensitivity. Ann Intern Med 1999;131:32-6.
14. Sepkowitz KA, Feldman J, Louther J, Rivera P, Villa N, DeHovitz J. Benefit of two-step PPD testing of new employees at a New York City hospital. Am J Infect Control 1997;25:283-6.
15. Menzies R, Vissandjee B, Rocher I, St Germain Y. The booster effect in two-step tuberculin testing among young adults in Montreal. Ann Intern Med 1994;120:190-8.
16. Rosenberg T, Manfreda J, Hershfield ES. Two-step tuberculin testing in staff and residents of a nursing home. Am Rev Respir Dis 1993;148:1537-40.
17. Slutkin G, Perez-Stable EJ, Hopewell PC. Time course and boosting of tuberculin reactions in nursing home residents. Am Rev Respir Dis 1986;134:1048-51.
18. Joven BE, Almodovar R, Galindo M, Mateo I, Pablos JL. Does anti-tumor necrosis factor alpha treatment modify the tuberculin PPD response. Ann Rheum Dis 2006;65:699.
19. Moreno S, Blazquez R, Novoa A, et al. The effect of BCG vaccination on tuberculin reactivity and the booster effect among hospital employees. Arch Intern Med 2001;161:1760-5.
20. Menzies D. Interpretation of repeated tuberculin tests. Boosting, conversion, and reversion. Am J Respir Crit Care Med 1999;159:15-21.
21. Ucan ES, Sevinc C, Abadoglu O, Arpaz S, Ellidokuz H. Tüberkülin Testi Sonuçlarinin Yorumlanmasi Ülkemiz Standartlari ve Yeni Gereksinimler. Toraks Dergisi 2000;1:25-30.
22. Helliwell MG, Panayi GS, Unger A. Delayed cutaneous hypersensitivity in rheumatoid arthritis: the influence of nutrition and drug therapy. Clin Rheumatol 1984;3:39-45.